Janssen R&D Ireland has entered a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (EDURANT) and ViiV's Integrase Inhibitor dolutegravir (TIVICAY), as the sole active ingredients for the maintenance treatment of HIV. The companies will also investigate development of the drug combination for pediatric use.
If approved, this treatment could offer an option for patients to switch from a standard three-drug therapy to a two-drug, Nucleoside Reverse Transcriptase Inhibitor (NRTI)-sparing antiviral regimen.
"HIV remains a significant medical challenge, and our goal is to find new treatment regimens for patients," said Paul Stoffels, chief scientific officer, Johnson & Johnson and Worldwide Chairman, Janssen. "We are pleased to collaborate with ViiV Healthcare in pursuing this shift in the HIV treatment paradigm and reaffirm our commitment to collaborate and develop new HIV treatments and fixed-dose regimens."